Companies: 10,795·Total market cap: $144.5T
Bioventus Inc.

Bioventus Inc.

BVSNASDAQHealthcare● Active
$9.04
+$0.34(+3.91%)
Market Cap$612442354
P/E Ratio—
52W High$11.249
52W Low$5.81
SEC Filings

Bioventus Inc. (BVS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001665988 · BVS · NASDAQ · as of Jun 8, 2026

Filing snapshot

457
Total Filings
4
Latest Form
2026-06-04
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001665988 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-05
Fiscal Year End
Mar 5, 2026
Accession No.
0001665988-26-000011
Primary Document
bvs-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001665988 · Accession 0001665988-26-000011

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-04
View
SDSD
SD
2026-05-29
View
8-KCurrent Report
8-K
2026-05-21
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
8-K
2026-05-06
View
ARSARS
ARS
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEF 14AProxy Statement
DEF 14A
2026-04-22
View
S-8Employee Stock Plan Registration
S-8
2026-03-05
View
10-KAnnual Report
10-K
2026-03-05
View
8-KCurrent Report
8-K
2026-03-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
3Initial Statement of Beneficial Ownership
FORM 3
2025-11-25
View
8-KCurrent Report
8-K
2025-11-17
View
10-QQuarterly Report
10-Q
2025-11-04
View
Showing 1–15 of 220 filingsForm 4 / 144 hidden· 457 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001665988  |  Exchange: NASDAQ · Healthcare

Bioventus Inc. (NASDAQ: BVS) has submitted 457 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001665988, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Bioventus Inc.'s most comprehensive regulatory disclosure. The most recent Bioventus Inc. 10-K was filed on 2026-03-05 for fiscal year ending 2026. Historical BVS 10-K annual reports are available from 2016 through 2026.

Investors researching Bioventus Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
BFLY SEC Filings →AVNS SEC Filings →CBLL SEC Filings →SRDX SEC Filings →CTKB SEC Filings →KIDS SEC Filings →LAB SEC Filings →VREX SEC Filings →
→ BVS Financials→ BVS Earnings→ BVS Insider Trades

Frequently Asked Questions

BVS SEC Filings · 8 questions

Bioventus Inc. (BVS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 457 filings and access original documents at no cost. Bioventus Inc.'s CIK is 0001665988.

BVS SEC filingsBioventus Inc. SEC documentsfind BVS 10-K